Replies to post #2556 on PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Kronberg]

Spideyboy my question about Fabrazyme' and Galafold' final approval came after I read the following

M.Manor "The decision to engage with the agency is also in light of the recent FDA designation of Fabry disease condition with a significant unmet need coupled with the fact there is currently no available therapy with final approval in the U.S. were the two commercial available therapies were approved on accelerated temporary basis with [indiscernible] market only where we believe our data set was minimum."

(the quote at the end of page 1)

https://seekingalpha.com/article/4219306-protalix-biotherapeutics-inc-plx-ceo-moshe-manor-q3-2018-results-earnings-call-transcript

After your answer, I am rather puzzled,by what M.Manor meant.